Research Article

miRNA-448 Regulates the Development of Glioblastoma (GBM) by Regulating Rho-Associated Protein Kinase 1

Chang Liu, Bin Zhu, Meng Zhong, and Jinsuo Bao

Neurosurgery Department, Affiliated Hospital of Inner Mongolia University for the Nationalities, Tongliao 028007, China

Correspondence should be addressed to Jinsuo Bao; baojinsuo@nmgmzdfsy.org.cn

Received 7 January 2022; Revised 16 February 2022; Accepted 19 February 2022; Published 3 March 2022

Academic Editor: Deepika Koundal

Copyright © 2022 Chang Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Glioblastoma (GBM) is an aggressive adult brain tumor that poses a huge threat to people’s health. Previous studies have shown that microRNAs (miRNAs) are important regulators in the progression of GBM. However, the role of miR-448 in GBM remains largely unknown. Therefore, the regulatory mechanism of miR-448 in the development of GBM is elucidated in this study.

Methods. The protein and mRNA expressions of miR-448 and ROCK1 were measured by Western blot analysis and RT-qPCR. Cell proliferation, migration, and invasion were detected by CCK-8 assay and Transwell assay. The relationship between miR-448 and ROCK1 was probed by luciferase reporter assay.

Results. miR-448 expression was downregulated in GBM tissues and cells. And poor clinical outcomes of GBM patients were related to miR-448 downregulation. Functionally, overexpression of miR-448 restrained cell viability, migration, and invasion in GBM. Additionally, miR-448 reduced ROCK1 expression by binding to its 3’-UTR. Moreover, knockdown of ROCK1 inhibited the progression of GBM. Furthermore, overexpression of ROCK1 abolished the antitumor effect of miR-448 in GBM.

Conclusion. miR-448 restrained cell viability, invasion, and migration in GBM by inhibiting ROCK1 expression.

1. Introduction

Glioblastoma (GBM) is a grade IV glioma, which mainly occurs in middle-aged people aged 40-60 years. The overall prognosis of GBM patients is poor [1]. Treatment of GBM is mainly neurosurgical resection, postoperative radiotherapy, and concurrent chemotherapy [2]. In general, the mean survival time of GBM patients after surgery, chemotherapy, and radiotherapy is approximately 14 months, and most GBM patients have a poor prognosis [3]. Today, targeted therapy and biological therapy have become the new direction of GBM treatment [4, 5] and also help to prolong the survival of patients. Therefore, exploring new therapeutic targets is of great significance for GBM patients.

It is well known that microRNAs (miRNAs) are involved in the regulation of cellular functions by negatively regulating target genes [6]. Moreover, increased miRNAs exhibit effects in GBM progression. miR-365 was downregulated and suppressed cell proliferation and migration by downregulating PAX6 in GBM [7]. Conversely, miR-374b was upregulated and promoted GBM progression by suppressing GATA3 [8]. These studies suggest that dysregulation of miRNAs is involved in the pathogenesis of GBM. Recently, the specific role of miR-448 has drawn our attention. For instance, downregulated miR-448 was found to alleviate spinal cord ischemia/reperfusion injury by upregulating SIRT1 [9]. In human ovarian and breast cancers, miR-448 expression was found to be reduced [10, 11]. Functionally, miR-448 restrained the invasion and proliferation of osteosarcoma cells [12]. In addition, miR-448 has been shown to play a critical role in suppressing pancreatic cancer [13]. However, the functional role of miR-448 in GBM has not been investigated in detail. Hence, this study is aimed at explaining the role of miR-448 in GBM.

In previous studies, Rho-associated protein kinase 1 (ROCK1) has been reported to play a role in malignancies. Increased expression of ROCK1 has been detected in gastric cancer and osteosarcoma [14, 15]. Furthermore, ROCK1 has been shown to accelerate cell growth and motility in pancreatic and prostate cancers [16, 17]. Additionally, ROCK1 has been shown to be involved in tumorigenesis by interacting with miR-202 or miR-124 [18, 19]. Besides that, it has been
2.3. RNA Isolation and RT-qPCR. TRIzol reagent (Sigma, 3000 (Invitrogen, Carlsbad, USA). were transfected into A-172 MG cells using Lipofectamine plasmids and siRNA (RiboBio, Guangzhou, China)

448 and ROCK1 was calculated by the 2\(^{-\Delta\Delta C_{T}}\) method. The relative expression of miR-448 and ROCK1 remains unclear in GBM. Therefore, this study involved some related experiments to demonstrate whether miR-448 plays a role in GBM by binding to ROCK1. Meanwhile, this study also explored how miR-448 regulates GBM progression. These findings will help to explain the molecular mechanism of miR-448 in the development of GBM.

2. Materials and Methods

2.1. Clinical Tissues. This study included 60 GBM patients from the Affiliated Hospital of Inner Mongolia University for the Nationalities. All patients signed the informed consent form and only underwent surgery. Our study was approved by the Institutional Ethics Committee of Affiliated Hospital of Inner Mongolia University for the Nationalities.

2.2. Cell Culture and Transfection. Primary normal human astrocytes (NHAs) and GBM cell lines A-172 MG, T98G were purchased from ATCC (Manassas, VA, USA). These cells were cultured in culture solution (90% DMEM+10% FBS), 5% CO\(_2\), and 37\(^{\circ}\)C.

suggested that ROCK1 mRNA has great diagnostic value in glioma patients [20]. And ROCK1 was found to promote glioma cell invasion [21]. However, the interaction between miR-448 and ROCK1 remains unclear in GBM. Therefore, this study involved some related experiments to demonstrate whether miR-448 plays a role in GBM by binding to ROCK1. Meanwhile, this study also explored how miR-448 regulates GBM progression. These findings will help to explain the molecular mechanism of miR-448 in the development of GBM.

2.3. RNA Isolation and RT-qPCR. TRIzol reagent (Sigma, 3000 (Invitrogen, Carlsbad, USA). were transfected into A-172 MG cells using Lipofectamine plasmids and siRNA (RiboBio, Guangzhou, China) were purchased from ATCC (Manassas, VA, USA). These cells were cultured in culture solution (90% DMEM+10% FBS), 5% CO\(_2\), and 37\(^{\circ}\)C.

miR-448 mimics and inhibitor or ROCK1 overexpression plasmids and siRNA (RiboBio, Guangzhou, China) were transfected into A-172 MG cells using Lipofectamine 3000 (Invitrogen, Carlsbad, USA).

2.4. Transwell Assay. Cell invasion was detected using Matrigel. A-172 MG cells (4 \(\times\) 10\(^{5}\) cells/well) were added to the upper chamber. DMEM medium (10% FBS) was added to the lower chamber to induce cell move. After 24 h incubation, the moving cells were stained with 0.1% crystal violet. With the exception of Matrigel, the steps of cell migration are the same as for invasion. Cell motility was observed with a light microscope.

2.5. CCK-8 Assay. A-172 MG cells (3 \(\times\) 10\(^{3}\) cells/well) were cultured in DMEM medium for 24, 48, 72, and 96 h. Then, 10 ml of CCK-8 (Dojindo, Kumamoto, Japan) was added to incubate the cells for 4 h. Finally, the optical density at 450 nm was measured by a microplate reader (Molecular Devices).

2.6. Dual Luciferase Reporter Assay. The pmirGLO luciferase reporter vector (Promega, USA) was inserted with Mut-ROCK1-3'UTR or Wt-ROCK1-3'UTR. Then, the luciferase vector was transfected into A-172 MG cells containing miR-448 mimics for 48 h. Luciferase activity was measured by dual luciferase assay system (Promega, USA).

2.7. Western Blot Analysis. RIPA buffer (Beyotime, Shanghai, China) was employed to lyse protein sample. Then, protein was separated by 10% SDS-PAGE. We transferred protein samples into PVDF membranes and blocked it with 5% non-fat milk. Then, protein was incubated overnight at 4\(^{\circ}\)C with Bax (rabbit polyclonal antibody; dilution, 1 : 500; cat. no. 137321), Bcl-2 (rabbit polyclonal; dilution, 1 : 500; cat. no. ab45171), ROCK1 (rabbit polyclonal; dilution, 1 : 1,000; cat. no. ab196495), and GAPDH (rabbit monoclonal, dilution, 1 : 1,000; cat. no. ab181602) primary antibodies (Abcam, Shanghai, China). After washing, the protein was continued to be incubated with secondary antibodies (mouse antirabbit, dilution, 1 : 2,000; cat. no. 58802; Abcam) for 1 h. Finally, protein bands were assessed by ECL kit (Beyotime). Quantity One 4.52 analysis software was used to measure the gray value of the bands. The relative expression of the target protein (IOD) = the gray value of the target protein/the gray value of the internal reference GAPDH.

2.8. Statistical Analysis. Data were analyzed by SPSS 17.0 and shown as mean ± SD. Figures were made with Graphpad Prism 6. Student’s t-test, Chi-squared test, and ANOVA with Turkey’s multiple comparison tests were used to calculate differences. P < 0.05 indicates a significant difference.

3. Results

3.1. miR-448 Was Downregulated in GBM. First, the expression of miR-488 was found to be lower in GBM tissues than in normal tissues (P < 0.01, Figure 1(a)). Compared with NHAs cells, miR-448 was also downregulated in A-172MG and T98G cells (P < 0.01, Figure 1(b)). Meanwhile, the histological grade of glioma patients was associated with dysregulation of miR-448 (Table 2; P < 0.05), suggesting that dysregulation of miR-448 indeed exists in GBM development. Then, we found that miR-448 mimics increased its expression, while miR-448 inhibitor decreased its expression in A-172MG cells (P < 0.01, Figure 1(c)).

| Primers | 5'-CTCAACTGTTGTCTGGGCA-3' | 5'-CAAAGTTGTCATGGATGHACC-3' |
|---------|-----------------------------|-------------------------------|
| miR-448 | 5'-TTGCATATATGAGGTATGCCCAAT-3' | 5'-CAAGTTGTCATGGATGHACC-3' |
| ROCK1   | 5'-GTTGAGTGGTGGTTGGGATTT-3' | 5'-CAAGTTGTCATGGATGHACC-3' |
| U6      | 5'-CCCTTCGGCGACACATATACTAC-3' | 5'-CAAGTTGTCATGGATGHACC-3' |
| GAPDH   | 5'-GTTGAAGGGTCCGAGTCACAG-3' | 5'-CAAGTTGTCATGGATGHACC-3' |

Table 1: The primers for RT-qPCR.
3.2. Overexpression of miR-448 Restrained GBM Progression.

Next, overexpression of miR-448 was found to inhibit cell proliferation, whereas downregulation of miR-448 accelerated A-172MG cell proliferation \((P < 0.01, \text{Figure } 2(a))\). As shown in Figure 2(b), miR-448 mimics promoted Bax expression and reduced Bcl-2 expression. Correspondingly, downregulation of miR-448 inhibited Bax expression and promoted Bcl-2 expression \((P < 0.01)\).

3.3. miR-448 Directly Targets ROCK1.

Furthermore, the TargetScan database (http://www.targetscan.org/) showed that miR-448 can bind to ROCK1 (Figure 3(a)). Next, a luciferase reporter assay showed that the miR-448 mimics reduced Wt-ROCK1 luciferase activity \((P < 0.01, \text{Figure } 3(b))\). In addition, ROCK1 expression was inhibited by miR-448 upregulation and promoted by miR-448 downregulation in A-172MG cells \((P < 0.01, \text{Figure } 3(c))\). Compared to normal tissues, ROCK1 was upregulated in GBM tissues \((P < 0.01, \text{Figure } 3(d))\). Meanwhile, miR-448 was also found to negatively regulate ROCK1 expression in GBM tissues \((P < 0.01, R^2 = 0.7078; \text{Figure } 3(e))\). The above results suggest that miR-448 reduces ROCK1 expression by binding to its 3’-UTR.

3.4. Knockdown of ROCK1 Impeded the Progression of GBM.

Next, the dysregulation of ROCK1 was detected in GBM. We found that the expression of ROCK1 was higher in A-172MG and T98G cells than in NHAs cells \((P < 0.01, \text{Table } 2)\).

**Table 2:** Relationship between miR-448 expression and their clinic-pathological characteristics of glioma patients.

| Characteristics | Cases | miR-448 | \(P\) value |
|-----------------|-------|---------|-------------|
| Age (years)     |       |         | 0.21        |
| ≥55             | 34    | 10      | 24          |
| <55             | 26    | 7       | 19          |
| Gender          |       |         | 0.38        |
| Male            | 36    | 12      | 24          |
| Female          | 24    | 5       | 19          |
| Tumor size (mm) |       |         | 0.31        |
| ≤5.0            | 12    | 6       | 6           |
| >5.0            | 48    | 11      | 37          |
| WHO grade       |       |         | 0.02*       |
| I-II            | 10    | 5       | 5           |
| III-IV          | 50    | 12      | 38          |

WHO: World Health Organization; statistical analyses were performed by the \(\chi^2\) test. \(*P < 0.05\) was considered significant.
Figure 4(a)). Then, A-172MG cells with ROCK1 siRNA were prepared to explore the role of ROCK1 in GBM. ROCK1 was found to be downregulated by its siRNA ($P < 0.01$, Figure 4(b)). Furthermore, ROCK1 knockdown inhibited cell proliferation in A-172MG cells ($P < 0.01$, Figure 4(c)). ROCK1 silencing enhanced Bax expression and decreased Bcl-2 expression in A-172MG cells ($P < 0.01$, Figure 4(d)). In addition, ROCK1 silencing suppressed cell migration.
and invasion ($P < 0.01$, Figures 4(e) and 4(f)). Combined with these results, ROCK1 is considered to be an oncogene in GBM.

3.5. Upregulation of ROCK1 Abolished the Suppressive Role of miR-448 in GBM. A-172MG cells with miR-448 mimics and ROCK1 vector were used to confirm the interaction of miR-448 and ROCK1 in GBM. ROCK1 vector restored the downregulation of ROCK1 induced by miR-448 mimics (Figure 5(a)). More importantly, miR-448 mimic-mediated inhibition of cell proliferation was impaired by upregulation of ROCK1 (Figure 5(b)). The reversal effect of ROCK1 on Bcl-2/Bax expression was also found in A-172MG cells (Figure 5(c)). Meanwhile, upregulation of ROCK1 attenuated the inhibitory effect of miR-448 on A-172MG cell migration and invasion (Figures 5(d) and 5(e)). Briefly, upregulation of ROCK1 restrains the antitumor effect of miR-448 in GBM.

4. Discussion

Recently, an increasing number of miRNAs are found to play carcinogenic or anticancer role in GBM. For example, miR-1225-5p has been reported to be downregulated and
act as a tumor inhibitor in GBM by targeting IRS1 [22]. Nonetheless, the regulatory mechanism of miR-448 in GBM has not been reported in previous studies. In this study, miR-448 was found to be downregulated and exert inhibitory effect in GBM. Specifically, we also found that downregulation of miR-448 was associated with histological grade of GBM patients. Our results also showed that upregulation of miR-448 inhibited cell viability, migration, and invasion in GBM. At the same time, upregulation of miR-448 induced apoptosis in GBM by reducing Bcl-2 expression and promoting Bax expression. To go much further, miR-448 suppressed ROCK1 expression by binding to its 3′-UTR. Moreover, upregulation of ROCK1 abolished the anti-tumor effect of miR-448 in GBM. Taken together, our findings reveal that miR-448 acts as a tumor suppressor in GBM through binding to ROCK1.

Figure 4: Knockdown of ROCK1 impeded the progression of GBM. (a) ROCK1 expression was measured in A-172MG, T98G, and NHAs cells. (b) ROCK1 expression was measured in A-172MG cells with its siRNA. (c) Cell proliferation in A-172MG cells with ROCK1 siRNA. (d) ROCK1 regulated protein expressions of Bax and Bcl-2 in A-172MG cells. (e, f) Cell migration and invasion in A-172MG cells with ROCK1 siRNA **P < 0.01.
Figure 5: Continued.
Recently, downregulation of miR-448 expression has been observed to be reduced in osteosarcoma and breast cancer [23, 24], which is consistent with our results. Additionally, low miR-448 expression has been reported to be associated with advanced tumor stage and metastasis in hepatocellular carcinoma [25]. Similarly, poor clinical outcomes in GBM patients were also found to be associated with downregulation of miR-448. Functionally, miR-448 inhibited the invasion and proliferation of gastric cancer cells by controlling ADAM10 [26]. Additionally, it was shown that miR-448 induced suppression of ovarian cancer cell metastasis by inhibiting CXCL2 [11]. These studies are consistent with our results. In addition to this, miR-448 was found to affect cell viability by regulating Bax/Bcl-2 in GBM. miR-448 exhibited effect in human cancers by mediating the expression of some genes such as IGF1R [27]. Here, miR-448 was found to be involved in GBM progression by interacting with ROCK1.

ROCK1, an oncogenic factor, has been found to be upregulated in osteosarcoma and colorectal cancer [28, 29]. Here, upregulation of ROCK1 was also detected in GBM. ROCK1 silencing was shown to inhibit the invasion, migration, and proliferation of laryngeal squamous cell carcinoma cells [30]. The present study also showed that ROCK1 has an oncogenic role in GBM, which is similar to previous studies. Moreover, miR-145 has been found to inhibit cell proliferation and promote apoptosis in hepatocellular carcinoma by downregulating ROCK1 [31]. miR-101 suppressed the invasion, migration, and proliferation of osteosarcoma cells by downregulating ROCK1 [32]. In our study, miR-448 was found to hinder the development of GBM by regulating ROCK1. All these findings suggest that the miR-448/ROCK1 axis is involved in GBM progression by inhibiting cell viability, invasion, and migration.

5. Conclusion
In conclusion, decreased miR-448 expression in GBM is associated with poor clinical outcomes. Furthermore, miR-448 restrains GBM progression by downregulating ROCK1. Although we have explained partial functions of miR-448 in GBM, the specific regulatory network of miR-448 needs to be explained in GBM.

Data Availability
Data to support the findings of this study is available on reasonable request from the corresponding author.

Ethical Approval
The study was approved by the Ethics Committee of Affiliated Hospital of Inner Mongolia University for the Nationalities.

Conflicts of Interest
The authors declare that they have no conflict of interests.

References
[1] V. M. Srinivasan, S. D. Ferguson, S. Lee, S. P. Weathers, B. C. P. Kerrigan, and A. B. Heimberger, "Tumor vaccines for malignant gliomas," *Neurotherapeutics*, vol. 14, no. 2, pp. 345–357, 2017.
[2] A. Omuro and L. M. DeAngelis, "Glioblastoma and other malignant gliomas," *JAMA*, vol. 310, no. 17, pp. 1842–1850, 2013.
[3] S. McNamara, "Treatment of primary brain tumours in adults," *Nursing Standard*, vol. 27, no. 14, pp. 42–47, 2012.
[4] T. H. H. Aldhyani and H. Alkahtani, “A bidirectional long short-term memory model algorithm for predicting COVID-19 in Gulf countries,” Life, vol. 11, no. 11, p. 1188, 2021.

[5] S. S. M. Khairi, M. A. A. Bakar, M. A. Alias et al., “Deep learning on histopathology images for breast cancer classification: a bibliometric analysis,” Healthcare, vol. 10, no. 1, p. 10, 2022.

[6] L. He and G. J. Hannon, "MicroRNAs: small RNAs with a big role in gene regulation," Nature Reviews. Genetics, vol. 5, no. 7, pp. 522–531, 2004.

[7] Y. Lv, Y. Lei, Y. Hu, W. Ding, C. Zhang, and C. Fang, "miR-374b targets GATA3 to promote progression and development of glioblastoma via regulating SEMA3B," Neoplasma, vol. 66, no. 4, pp. 543–554, 2019.

[8] J. Gao, S. Bai, Y. Wang, S. Zhao, Z. He, and R. Wang, "miR-124 regulates GABRA3 to promote progression and development of glioblastoma via regulating SEMA3B," American Journal of Translational Research, vol. 11, no. 1, pp. 361–369, 2019.

[9] J. Gao, S. Bai, Y. Wang, S. Zhao, Z. He, and R. Wang, "miR-374b targets GATA3 to promote progression and development of glioblastoma via regulating SEMA3B," Neoplasma, vol. 66, no. 4, pp. 543–554, 2019.

[10] P. Ma, K. Ni, J. Ke, W. Zhang, Y. Feng, and Q. Mao, "miR-448 inhibits the epithelial-mesenchymal transition in breast cancer cells by directly targeting the E-cadherin repressor REB1/2," Experimental Biology and Medicine, vol. 243, no. 5, pp. 473–480, 2018.

[11] Y. Lv, Y. Lei, Y. Hu, W. Ding, C. Zhang, and C. Fang, "miR-448 negatively regulates ovarian cancer cell growth and metastasis by targeting CXCL12," Clinical & Translational Oncology, vol. 17, no. 11, pp. 903–909, 2015.

[12] X. Wu, L. Yan, Y. Liu, W. Xian, L. Wang, and X. Ding, "MicroRNA-448 suppresses osteosarcoma cell proliferation and invasion through targeting EPHA7," PLoS One, vol. 12, no. 6, article e0175553, 2017.

[13] H. Y. Liu, J. Chang, G. D. Li, Z. H. Zhang, J. Tian, and Y. S. Mu, "MicroRNA-448/EPHA7 axis regulates cell proliferation, invasion and migration via regulation of PI3K/AKT signaling pathway and epithelial-to-mesenchymal transition in non-small cell lung cancer," European Review for Medical and Pharmacological Sciences, vol. 24, no. 11, pp. 6139–6149, 2020.

[14] Y. J. Wu, Y. Tang, Z. F. Li et al., "Expression and significance of Rac1, Pak1 and Rock1 in gastric carcinoma," Asia-Pacific Journal of Clinical Oncology, vol. 10, no. 2, pp. e33–e39, 2014.

[15] C. H. Li, T. B. Yu, H. W. Qiu, X. Zhao, C. L. Zhou, and C. Qi, "miR-150 is downregulated in osteosarcoma and suppresses cell proliferation, migration and invasion by targeting ROCK1," Oncology Letters, vol. 13, no. 4, pp. 2191–2197, 2017.

[16] C. Vennin, N. Rathi, M. Pajic, M. F. Olson, and P. Timpson, "Targeting ROCK activity to disrupt and prime pancreatic cancer for chemotherapy," Small GTPases, vol. 11, no. 1, pp. 45–52, 2020.

[17] B. Xu, Y. Huang, X. Niu et al., "Hsa-miR-146a-5p modulates androgen-independent prostate cancer cells apoptosis by targeting ROCK1," Prostate, vol. 75, no. 16, pp. 1896–1903, 2015.

[18] F. Xu, H. Li, and C. Hu, "miR-202 inhibits cell proliferation, invasion, and migration in breast cancer by targeting ROCK1 gene," Journal of Cellular Biochemistry, vol. 120, no. 9, pp. 16008–16018, 2019.

[19] L. Zhou, Z. Xu, X. Ren, K. Chen, and S. Xin, "MicroRNA-124 (miR-124) inhibits cell proliferation, metastasis and invasion in colorectal cancer by downregulating rho-associated protein kinase 1 (ROCK1)," Cellular Physiology and Biochemistry, vol. 38, no. 5, pp. 1785–1795, 2016.

[20] Y. Liu, J. Zhang, D. Wang, and X. Yang, "Serum ROCK1 mRNA is of great diagnostic value for glioma patients," Medicine (Baltimore), vol. 98, no. 19, article e15413, 2019.

[21] X. Wan, Q. Cheng, R. Peng et al., "ROCK1, a novel target of miR-145, promotes glioma cell invasion," Molecular Medicine Reports, vol. 9, no. 5, pp. 1877–1882, 2014.

[22] L. Li, G. Chi, Z. Chen, and X. Jin, "MicroRNA-1225-5p behaves as a tumor suppressor in human glioblastoma via targeting of IRS1," Oncotargets and Therapy, vol. Volume 11, pp. 6339–6350, 2018.

[23] O. A. Bamodu, W. C. Huang, W. H. Lee et al., "Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448," BMC Cancer, vol. 16, no. 1, p. 160, 2016.

[24] X. Wu, H. Tang, G. Liu, H. Wang, J. Shu, and F. Sun, "miR-448 suppressed gastric cancer proliferation and invasion by regulating ADAM10," Tumour Biology, vol. 37, no. 8, pp. 10545–10551, 2016.

[25] B. Li, L. Ge, M. Li, L. Wang, and Z. Li, "miR-448 suppresses proliferation and invasion by regulating IGFIR in colorectal cancer cells," American Journal of Translational Research, vol. 8, no. 7, pp. 3013–3022, 2016.

[26] J. L. Liu, J. Li, J. J. Xu et al., "miR-144 inhibits tumor growth and metastasis in osteosarcoma via dual-suppressing RhoA/ROCK1 signaling pathway," Molecular Pharmacology, vol. 95, no. 4, pp. 451–461, 2019.

[27] Q. D. Zhu, Q. Q. Zhou, L. Dong, Z. Huang, F. Wu, and X. Deng, "miR-199a-5p inhibits the growth and metastasis of colorectal cancer cells by targeting ROCK1," Technology in Cancer Research & Treatment, vol. 17, p. 153303461877550, 2018.

[28] Y. Liu, J. Liu, L. Wang, X. Yang, and Y. Liu, "MicroRNA195 inhibits cell proliferation, migration and invasion in laryngeal squamous cell carcinoma by targeting ROCK1," Molecular Medicine Reports, vol. 16, no. 5, pp. 7154–7162, 2017.

[29] R. K. Wang, X. M. Shao, J. P. Yang, H. L. Yan, and Y. Shao, "MicroRNA-145 inhibits proliferation and promotes apoptosis of HepG2 cells by targeting ROCK1 through the ROCK1/NF-kB signaling pathway," European Review for Medical and Pharmacological Sciences, vol. 23, no. 7, pp. 2777–2785, 2019.

[30] R. Jiang, C. Zhang, G. Liu, R. Gu, and H. Wu, "MicroRNA-101 inhibits proliferation, migration and invasion in osteosarcoma cells by targeting ROCK1," American Journal of Cancer Research, vol. 7, no. 1, pp. 88–97, 2017.